Last reviewed · How we verify
Target INR 1.8
The drug aims to maintain the International Normalized Ratio (INR) at 1.8 to prevent thrombosis while minimizing bleeding risk.
The drug aims to maintain the International Normalized Ratio (INR) at 1.8 to prevent thrombosis while minimizing bleeding risk. Used for Prevention of thromboembolic events in patients with atrial fibrillation.
At a glance
| Generic name | Target INR 1.8 |
|---|---|
| Sponsor | Washington University School of Medicine |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It likely modulates the coagulation pathway to achieve a balanced anticoagulant effect, ensuring that the blood's clotting tendency remains within a safe and effective range.
Approved indications
- Prevention of thromboembolic events in patients with atrial fibrillation
Common side effects
- Bleeding
Key clinical trials
- INR-Triggered Transfusion In GI Bleeders From ER (PHASE3)
- Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT (PHASE3)
- BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Target INR 1.8 CI brief — competitive landscape report
- Target INR 1.8 updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI